Sickness, Social Isolation, and a Solution: A Brief Exploration of COVID-19 Related Depression and Transcranial Direct Current Stimulation

Fariha Khan¹, Peter Anto Johnson²*, John Christy Johnson³, Jasrita Singh⁴, Austin Mardon⁵

¹,²,³,⁴,⁵Antarctic Institute of Canada, Canada

Abstract

The COVID-19 pandemic has illuminated a need for accessible, home-based therapies for mental health. In an era of social distancing, lockdowns, and declining global mental health, one promising candidate is transcranial Direct Current Stimulation (tDCS). tDCS is a non-invasive, portable, targeted brain stimulation technique that uses electrical currents to modulate cortical excitability. It has been heavily explored as a treatment for major depressive disorder (MDD) and other mental health issues in recent years. However, before such a treatment may become widespread, certain research questions must be addressed, and safety outcomes must be thoroughly evaluated. This article aims to provide a brief overview of tDCS, the COVID-19 pandemic’s impact on mental health, and tDCS’ potential to be used in such a situation. The article also explores some of the drawbacks and challenges that lie in the way of tDCS being normalized as a mental health therapeutic.

Introduction

The World Health Organization (WHO) declared COVID-19 to be a Public Health Emergency of International Concern (PHEIC) in late January of 2020, and only a few short months later in mid March, it became a global pandemic. Governments around the world began responding by taking measures to limit social contact in hopes of reducing transmission and curbing the spread.
of the virus. China, where the outbreak was first reported, took early and aggressive measures by implementing travel restrictions, shutting down public transport, closing public spaces, prohibiting large gatherings, and giving a stay-at-home self-quarantine order [1]. Many other countries soon adopted similar pursuits and continue to hold alternating periods of loosened and heightened restrictions as COVID-19 cases slow and surge. However, the psychological costs of quarantine are high; social isolation has previously been linked with depression, stress, and negative mood [2, 3]. Indeed, in Canada alone, there was a 13 percentage point decrease in the amount of Canadians who self-reported as having good mental health, down from 68% in 2019 to 55% in July 2020 [4]. Youth aged 15-24 specifically report the most drastic declines, down from 60% pre-pandemic to 40% in July 2020 [4]. In the United States, the rates of depressive symptoms increased three-fold post-pandemic [5]. Humans are social beings, and our interactions with others are important for positive health outcomes, both physical and mental [6]. To be deprived of these interactions can have adverse effects on psychological well-being, something that is now becoming apparent across Canada and the globe.

How then, can the increasing number of individuals requiring psychological help access mental healthcare resources in an era of social isolation such as this one? One answer may lie in the prospect of at-home treatments such as transcranial Direct Current Stimulation (tDCS), a non-invasive and painless targeted brain stimulation technique that is being explored as a treatment option for multiple neuropsychiatric conditions, including depression. A constant, low-intensity current, typically 0.5-2.0 mA, flows through two conductive electrodes that are placed onto the head of a patient, using a specified area of the brain to complete the circuit. The stimulation can either be anodal- acting to excite neuronal activity or cathodal- acting to inhibit neuronal activity. Anodal stimulation works to depolarize neuronal membranes which then increases the probability that the neurons will undergo action potentials and fire, while cathodal stimulation hyperpolarizes neuronal membranes, decreasing the probability that they will fire. In the treatment of depression, tDCS aims to combat left dorsolateral prefrontal cortex (DLPFC) underactivity - an imbalance that is hypothesised to be one of the biological causes of depression - through anodal stimulation and thus the increase of cortical activity in the area. tDCS may be administered alone or in conjunction with other psychological therapies and medications; however, results of tDCS and pharmacotherapy have been varied, either enhancing tDCS effects or abolishing them, and more research is required [7].

**Clinical Efficacy of tDCS**

Numerous studies have demonstrated the effectiveness of tDCS. A study by Fregni et al. (2006) following 10 patients with major depressive disorder (MDD) showed positive results and improvement of depressive symptoms after five 10-minute long sessions of 1 mA anodal tDCS where patients in the active treatment group experienced a 60% reduction in Hamilton Depression Rating Scale (HDRS) scores [8]. Comparatively, patients in a placebo (sham) treatment only experienced an HDRS reduction of 10% [8]. Boggio et al. (2008) found similar antidepressant effects in a clinical trial consisting of 40 patients with MDD where after ten 20-minute long sessions of 2 mA anodal tDCS, there was a 40.4% reduction in HDRS scores for those in the active treatment group, while patients in the sham treatment group only experienced an HDRS reduction of 10.4% [9]. The effects experienced by those in the active treatment group persisted for one month after the tDCS sessions had ended [9]. In another trial of 64 depressed
patients who underwent fifteen 20-minute long sessions of 2 mA anodal tDCS, Loo et al. (2012) found a 28.4% improvement in Montgomery-Asberg Depression Rating Scale (MADRS) scores for the active treatment group, compared to only a 15.9% improvement in the sham group [10]. A meta-analysis of these studies as well as sixteen others found similar results, where active tDCS treatments were superior to sham in reducing depressive symptoms [11]. Overall, the increased improvements of the active groups in these studies shows promising potential of tDCS as a treatment for MDD.

**Advantages of tDCS**

tDCS is inexpensive, non-invasive, and the equipment is reusable and easy to replace. The cost of a basic consumer-grade tDCS device could be as low as 100USD. Perhaps most importantly and most relevant to our current global climate, however, is the potential for tDCS to be used at home. The manufacture of portable tDCS devices could eliminate the need for visits to clinics and would allow for the maintenance of social distancing guidelines. However, it is important to note that this would require thoroughly training a patient in the proper usage of tDCS, something that may be tricky or cumbersome for some users and discourage them from continuing with treatment.

As well, tDCS may offer an alternative course of action for patients with treatment-resistant depression who have failed to find relief in conventional clinical therapy and psychotropics. 30% of patients with depression do not see substantial results from traditional therapies [12, 13]. Indeed, Palm et al. (2009) found modest improvement of treatment-resistant depression in a patient after 16 tDCS sessions [14]. tDCS efficacy is, however, lowered in those with treatment-resistant depression [11]. tDCS also offers the advantage of having minimal side effects compared to drug treatments such as SSRIs which have been linked with causing sexual dysfunction, weight gain, nausea, anxiety, and other unpleasant side effects [15]. Many patients also find the prescribed doses of their medications to be inadequate or aggressive, something that may be caused by the individual variation in drug metabolization [16]. The challenges associated with drug therapies can become intolerable for some patients and lead to treatment discontinuation. Other individuals, such as pregnant or breastfeeding women, may not be able to take medications at all without risking harm to their developing fetus or child. tDCS, which is localized to the brain, could theoretically be offered as an alternative in such a case as well; however, this is an area requiring more research as safety outcomes for this group have not yet been evaluated [17, 18].

**Safety and Other Considerations**

However, tDCS is not entirely free from side effects. Most commonly, mild itching and tingling has been reported. Patients have also experienced temporary skin irritation, headaches, burning, and lesions due to dry electrode sponges [19]. However, no serious adverse effect has been reported nor have there been any irreversible injuries [19]. Brain lesions were only induced in rats when they were delivered a charge density two orders of magnitude higher than the charge density currently administered to humans [20]. tDCS sessions involving vulnerable individuals such as those with geriatric depression, children with cerebral palsy, and post-stroke aphasia patients also supported safety [21, 22, 23]. Repeated exposure to the treatment has also been
shown to be safe; depressed patients who underwent over 100 sessions displayed no serious adverse effects [24].

A notable phenomenon has also been found with tDCS, certain tasks involving motor and a cognitive activity performed during stimulation can interfere with and abolish the effects of tDCS. In one study, completing a questionnaire such as a math quiz or pushing a ball resulted in modified tDCS efficacy [25]. The cognitive task resulted in motor cortex excitability lower after anodal stimulation and higher after cathodal stimulation while the motor task lowered motor cortex excitability after both anodal and cathodal stimulation [25]. If the effects of tDCS can be abolished through specific states of a participant during stimulation, this could be problematic - especially when considering the usage of home-based tDCS. Patients facing distractions or simply experiencing certain cognitions could have the effects of their tDCS treatment nullified. Once again, this is why potential users must be thoroughly trained and educated before beginning treatment. These findings also open the door for more future research to be done. Much is still not understood about tDCS, and the effects of interference found in this study as well as others have not been discussed enough [26].

Conclusion
tDCS is promising for the future of accessible mental healthcare and neurotherapeutics, something that is required now in this era of social isolation more than ever. However, despite the COVID-19 induced mental health crisis and the growing need for social-distancing-safe resources, tDCS as a novel treatment currently lacks FDA-approval and is still surrounded by stigma and uncertainties. More research, work, and education must be done before such a therapy may become a wide-spread treatment route for depression. Specifically, safety outcomes for vulnerable groups such as pregnant women, the effects of tDCS in conjunction with certain medications, and potential challenges for home-based users should be assessed. The interference effect is also an area that must be looked into further and addressed through coming research. As stated by Horvath et al. (2014), “rather than seeing [issues] as a detriment to the field, we should use them to guide future research and exploration” [26].

Declarations
Acknowledgements
Not applicable.

Disclosure Statement
No potential conflict of interest was reported by the authors.

Ethics Approval
Not applicable.

Funding Acknowledgements
Not applicable.

Citation to this article
Fariha K, Peter AJ, John CJ, Jasrita S, Austin M. Sickness, social isolation, and a solution: A brief exploration of COVID-19 related depression and transcranial direct current stimulation. Canadian Journal of Medicine. 2022 April 24;4(1):26-31. doi: 10.33844/cjm.2022.6018

Rights and Permissions

© 2022 Canadian Institute for Knowledge Development. All rights reserved.

Canadian Journal of Medicine is published by the Canadian Institute for Knowledge Development (CIKD). This is an open-access article under the terms of the Creative Commons Attribution (CC BY) License, which permits use, distribution, and reproduction in any medium, provided the original work is properly cited.

References

[1] Liu W, Yue XG, Tchounwou PB. Response to the COVID-19 Epidemic: The Chinese Experience and Implications for Other Countries. Int J Environ Res Public Health. 2020 Mar 30;17(7):2304.

[2] Matthews T, Danese A, Wertz J, Odgers CL, Ambler A, Moffitt TE, Arseneault L. Social isolation, loneliness and depression in young adulthood: a behavioural genetic analysis. Soc Psychiatry Psychiatr Epidemiol. 2016 Mar;51(3):339-48.

[3] Brooks SK, Webster RK, Smith LE, Woodland L, Wessely S, Greenberg N, Rubin GJ. The psychological impact of quarantine and how to reduce it: rapid review of the evidence. Lancet. 2020 Mar 14;395(10227):912-920.

[4] Statistics Canada. The Social and Economic Impacts of COVID-19: A Six-month Update, https://www150.statcan.gc.ca/n1/pub/11-631-x/2020004/s3-eng.htm#moreinfo; 2020 [accessed 15 April 2021]

[5] Ettman CK, Abdalla SM, Cohen GH, Sampson L, Vivier PM, Galea S. Prevalence of Depression Symptoms in US Adults Before and During the COVID-19 Pandemic. JAMA Netw Open. 2020 Sep 1;3(9):e2019686.

[6] Seeman TE. Social ties and health: the benefits of social integration. Ann Epidemiol. 1996 Sep;6(5):442-51.

[7] Brunoni AR, Ferrucci R, Fregni F, Boggio PS, Priori A. Transcranial direct current stimulation for the treatment of major depressive disorder: a summary of preclinical, clinical and translational findings. Prog Neuropsychopharmacol Biol Psychiatry. 2012 Oct 1;39(1):9-16.

[8] Fregni F, Boggio PS, Nitsche MA, Marcolin MA, Rigonatti SP, Pascual-Leone A. Treatment of major depression with transcranial direct current stimulation. Bipolar Disord. 2006 Apr;8(2):203-4.

[9] Boggio PS, Rigonatti SP, Ribeiro RB, Myczkowski ML, Nitsche MA, Pascual-Leone A, Fregni F. A randomized, double-blind clinical trial on the efficacy of cortical direct current stimulation for the treatment of major depression. Int J Neuropsychopharmacol. 2008 Mar;11(2):249-54.

[10] Loo CK, Alonzo A, Martin D, Mitchell PB, Galvez V, Sachdev P. Transcranial direct current stimulation for depression: 3-week, randomised, sham-controlled trial. Br J Psychiatry. 2012 Jan;200(1):52-9.

[11] Brunoni AR, Valiengo L, Baccaro A, Zanão TA, de Oliveira JF, Goulart A, Boggio PS, Lotufo PA, Benseñor IM, Fregni F. The sertraline vs. electrical current therapy for treating depression clinical study: results from a factorial, randomized, controlled trial. JAMA Psychiatry. 2013 Apr;70(4):383-91.

[12] Rush AJ, Trivedi MH, Wisniewski SR, Nierenberg AA, Stewart JW, Warden D, Nemeroff C, Thase ME, Lavori PW, Lebowitz BD, McGrath PJ, Rosenbaum JF, Sackeim HA, Kupfer DJ, Luther J, Fava M. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry. 2006 Nov;163(11):1905-17.

[13] Trivedi MH, Rush AJ, Wisniewski SR, Nierenberg AA, Warden D, Ritz L, Norquist G, Howland RH, Lebowitz B, McGrath PJ, Shores-Wilson K, Biggs MM, Balasubramani GK, Fava M; STAR*D Study Team. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am J Psychiatry. 2006 Jan;163(1):28-40.

[14] Palm U, Keeser D, Schiller C, Fintescu Z, Reisinger E, Baghai TC, Mulert C, Pabergen F. Transcranial direct current stimulation in a patient with therapy-resistant major depression. World J Biol Psychiatry. 2009;10(4 Pt 2):632-5.
[15] Ferguson JM. SSRI antidepressant medications: Adverse effects and tolerability. Prim Care Companion J Clin Psychiatry. 2001 Feb;3(1):22-27.

[16] Correia MA. Drug biotransformation. In: Katung G, editor. Basic and clinical pharmacology. 6th ed. Appleton and Lange, 1995:48-60.

[17] Kurzcek AK, Kirsch B, Weidinger E, Padberg F, Palm U. Transcranial Direct Current Stimulation (tDCS) for depression during pregnancy: Scientific evidence and what is being said in the media-a systematic review. Brain Sci. 2018 Aug 14;8(8):155.

[18] Vigod S, Dennis CL, Daskalakis Z, Murphy K, Ray J, Oberlander T, Somerton S, Hussain-Shamsy N, Blumberger D. Transcranial direct current stimulation (tDCS) for treatment of major depression during pregnancy: study protocol for a pilot randomized controlled trial. Trials. 2014 Sep 18;15:366.

[19] Bikson M, Grossman P, Thomas C, Zannou AL, Jiang J, Adnan T, Mourdoukoutas AP, Kronberg G, Truong D, Boggio P, Brunoni AR, Charvet L, Fregni F, Fritsch B, Gillick B, Hamilton RH, Hampstead BM, Jankord R, Kirton A, Knotkova H, Liebetanz D, Liu A, Loo C, Nitsche MA, Reis J, Richardson JD, Rotenberg A, Turkeltaub PE, Woods AJ. Safety of transcranial direct current stimulation: Evidence Based Update 2016. Brain Stimul. 2016 Sep-Oct;9(5):641-661.

[20] Liebetanz D, Koch R, Mayenfels S, König F, Paulus W, Nitsche MA. Safety limits of cathodal transcranial direct current stimulation in rats. Clin Neurophysiol. 2009 Jun;120(6):1161-7.

[21] Gálvez V, Ho KA, Alonzo A, Martin D, George D, Loo CK. Neuromodulation therapies for geriatric depression. Curr Psychiatry Rep. 2015 Jul;17(7):59.

[22] Grecco LA, Duarte NA, Zanon N, Galli M, Fregni F, Oliveira CS. Effect of a single session of transcranial direct-current stimulation on balance and spatiotemporal gait variables in children with cerebral palsy: A randomized sham-controlled study. Braz J Phys Ther. 2014 Sep-Oct;18(5):419-27.

[23] Vestito L, Rosellini S, Mantero M, Bandini F. Long-term effects of transcranial direct-current stimulation in chronic post-stroke aphasia: a pilot study. Front Hum Neurosci. 2014 Oct 14;8:785.

[24] Tadini L, El-Nazer R, Brunoni AR, Williams J, Carvas M, Boggio P, Priori A, Pascual-Leone A, Fregni F. Cognitive, mood, and electroencephalographic effects of noninvasive cortical stimulation with weak electrical currents. J ECT. 2011 Jun;27(2):134-40.

[25] Antal A, Terney D, Poreisz C, Paulus W. Towards unravelling task-related modulations of neuroplastic changes induced in the human motor cortex. Eur J Neurosci. 2007 Nov;26(9):2687-91.

[26] Horvath JC, Carter O, Forte JD. Transcranial direct current stimulation: five important issues we aren't discussing (but probably should be). Front Syst Neurosci. 2014 Jan 24;8:2